Back to search results

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Abroad (travel likely)RecruitingPHASE3

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hospital das Clinicas da FMRP USP, Ribeirão Preto, São Paulo, Brazil

  • Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil

  • CISSS-CA, Lévis, Quebec, Canada

  • Universita Cattolica del Sacro Cuore - Policlinico Universitario A. Gemelli, Rome, Lazio, Italy

  • AOU Careggi, Florence, Tuscany, Italy

  • SC Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy

  • In-Vivo Sp. z o.o., Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Seoul National University Hospital, Seoul, South Korea

  • Severance Hospital, Seoul, South Korea

  • Seoul St. Mary's Hospital - The Catholic University of Korea, Seoul, South Korea

  • Ewha Womans University Mokdong Hospital, Seoul, South Korea

  • Samsung Medical Center, Seoul, South Korea

  • Hospital Universitario Basurto, Bilbao, Vizcaya, Spain

  • Institut Catala d'Oncologia, Barcelona, Spain

  • Hospital San Pedro de Alcantara, Cáceres, Spain

  • Hospital General JM Morales Meseguer, Murcia, Spain

  • Hospital Universitario de Salamanca, Salamanca, Spain

  • Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey (Türkiye)

  • Ege University, Izmir, Turkey (Türkiye)

Study leads

  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)